What is Paragon Genomics?
Headquartered in Hayward, California, Paragon Genomics specializes in the development and commercialization of rapid, ultra-high multiplex PCR-based target enrichment solutions. The company's proprietary technology is engineered to streamline the NGS workflow, providing researchers and clinicians with high-fidelity data while reducing operational complexity. By addressing the critical bottleneck of target enrichment, Paragon Genomics has established itself as an essential partner for laboratories seeking to scale their sequencing capabilities across oncology, infectious disease, and inherited disorder research.
How much funding has Paragon Genomics raised?
Paragon Genomics has raised a total of $8.3M across 2 funding rounds:
Series A
$8M
Debt
$350K
Series A (2017): $8M with participation from Wisemont Capital, Cowin Venture Capital, and HEDA Ventures
Debt (2020): $350K led by PPP
Key Investors in Paragon Genomics
Wisemont Capital
Wisemont Capital is an early-stage venture capital firm based in Silicon Valley, specializing in investments in AI, SaaS, and automation sectors. The firm focuses on nurturing groundbreaking startups in the U.S. and helping them scale globally through expertise in cross-border business strategies.
Cowin Venture Capital
Established in 2000, Cowin Capital is a prominent Chinese venture capital firm with a high success rate in taking portfolio companies to domestic IPOs, focusing on high-quality enterprises across various technology and life science sectors.
HEDA Ventures
HEDA Ventures operates as a strategic investment arm with deep ties to industrial manufacturing and telecommunications, providing capital and operational expertise to companies looking to optimize their supply chain and market reach.
What's next for Paragon Genomics?
With the recent influx of capital, Paragon Genomics is well-positioned to accelerate its commercial expansion and deepen its R&D pipeline. The company is expected to focus on scaling its manufacturing capacity to meet the rising global demand for precision medicine tools. Furthermore, the strategic backing from its investor syndicate provides the necessary operational leverage to penetrate new international markets and enhance its product portfolio, ensuring that the firm remains at the vanguard of the rapidly evolving genomics landscape.
See full Paragon Genomics company page
